Psoriatic arthritis: recent progress in pathophysiology and drug development

@inproceedings{Veale2013PsoriaticAR,
  title={Psoriatic arthritis: recent progress in pathophysiology and drug development},
  author={Douglas J Veale},
  booktitle={Arthritis research & therapy},
  year={2013}
}
Psoriatic arthritis (PsA) is the second most common inflammatory arthropathy, after rheumatoid arthritis diagnosis, in early arthritis clinics. Most patients have established psoriasis, often for years, prior to the onset of joint pain and swelling; in addition, associated features of nail disease, dactylitis, enthesitis, spondylitis or uveitis may be present. Psoriasis may not be immediately apparent, as small or patchy lesions may occur in the scalp or perineum. PsA presents as a symmetrical… CONTINUE READING
4 Citations
48 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis

  • A Kavanaugh, PJ Mease, +5 authors JJ Gomez-Reino
  • Ann Rheum Dis 2013,
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…